NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
30/06/2026
Voltar para busca
Dado oficial do USPTO
TMOD
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
53
Atualização mais recente
30/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
09/12/2020
Data de registro
30/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
30/06/2026
Última transação
30/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/05/2023
Primeiro uso no comércio
01/05/2023
Código do desenho
4
Tipo de titular
03
Localização do titular
Agoura Hills, CA, US
Examinador
KELLY, JOHN M
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
A2 Biotherapeutics, Inc.
Representantes
Joi A. White CARR & FERRELL LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
pharmaceutical products for the treatment and prevention of cancer; therapeutic targetsproteins or protein complexesfor the treatment and prevention of cancer; therapeutic cellstherapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer; engineered cell therapies in the nature of proteins and protein complexes for medical purposesthe treatment and prevention of cancer; engineered cell therapy platforms consisting of modified cellscell receptorsproteins and protein complexes; cell platforms consisting of modified cellscell receptorsproteins and protein complexes for the treatment and prevention of cancer; biological technology platforms consisting of modified cellscell receptorsproteins and protein complexes for developing and engineering therapeutic cellstherapeutic proteinstherapeutic antibodiestherapeutics and cellular therapies for the treatment and prevention of cancer; cell platform consisting of modified cellscell receptorsproteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer; gene therapy productsgenetically engineered tissues for transplant purposes
Classe 40
custom manufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancer; biomanufacturing for othersmanufacturing of cellstherapeutics and cell therapies for the treatment and prevention of cancerusing biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cellsproteinsantibodies for others for treatment and prevention of cancer
Classe 42
Identification and development oftherapeutic targetsproteins and protein complexesfor others for the treatment and prevention of cancer; development of therapeutics and cell therapies for the treatment and prevention of cancer; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer; biotechnology researchdevelopmenttesting and analysis for the treatment of cancer; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer; researchdevelopmentengineering and testing services in the fields of therapeuticscell therapiesbiologicsmedicinepharmaceuticals; medical laboratory servicestissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cellscellular targetsproteinsantibodies for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
53 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
30/06/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
08/06/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/06/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
21/04/2026
IUAF
USE AMENDMENT FILED
24/11/2025
EISU
TEAS STATEMENT OF USE RECEIVED
24/11/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/08/2025
EX5G
SOU EXTENSION 5 GRANTED
11/08/2025
EXT5
SOU EXTENSION 5 FILED
14/05/2025
EEXT
SOU TEAS EXTENSION RECEIVED
14/05/2025
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/10/2024
EX4G
SOU EXTENSION 4 GRANTED
22/10/2024
EXT4
SOU EXTENSION 4 FILED
22/10/2024
EEXT
SOU TEAS EXTENSION RECEIVED
22/10/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
15/05/2024
EX3G
SOU EXTENSION 3 GRANTED
14/05/2024
EXT3
SOU EXTENSION 3 FILED
14/05/2024
EEXT
SOU TEAS EXTENSION RECEIVED
14/05/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
21/11/2023
EX2G
SOU EXTENSION 2 GRANTED
17/11/2023
EXT2
SOU EXTENSION 2 FILED
17/11/2023
EEXT
SOU TEAS EXTENSION RECEIVED
17/11/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/05/2023
EX1G
SOU EXTENSION 1 GRANTED
09/05/2023
EXT1
SOU EXTENSION 1 FILED
09/05/2023
EEXT
SOU TEAS EXTENSION RECEIVED
09/05/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/11/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/09/2022
PUBO
PUBLISHED FOR OPPOSITION
27/09/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/09/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/08/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/08/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/08/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/07/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/07/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
22/05/2022
GNRT
NON-FINAL ACTION E-MAILED
22/05/2022
CNRT
NON-FINAL ACTION WRITTEN
22/05/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
06/04/2022
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
08/03/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/02/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/02/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/02/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/02/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
18/08/2021
GNRT
NON-FINAL ACTION E-MAILED
18/08/2021
CNRT
NON-FINAL ACTION WRITTEN
18/08/2021
DOCK
ASSIGNED TO EXAMINER
28/05/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/02/2021
NWAP
NEW APPLICATION ENTERED
12/12/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TMOD ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.